Endpoints News
@endpts.com
We're where the business of medicine gets answers. An independent news media organization covering biotech, pharma, science, policy, finance, venture capital and markets, and how they drive the life sciences industry. Read us at www.endpts.com.
Pinned
Endpoints News
@endpts.com
· Dec 17
Just finding us here? Endpoints News has a starter pack with our journalists so you can follow the team!
go.bsky.app/NzDRUhL
go.bsky.app/NzDRUhL
#JPM26 takeaway? GLP-1s are hot. “Every time you mention GLP-1, I’m going to charge you $5. I’m going to donate it to, I don’t know, an injured Canadian seals fund or something like that," Sandoz CEO Richard Saynor said.
endpoints.news/jpm26-sandoz...
endpoints.news/jpm26-sandoz...
Generic GLP-1s are coming this year. The CEO in charge doesn't know what to expect
As Sandoz prepares to launch what could be the world's first generic version of Novo's Ozempic in Canada and possibly Brazil in 2026, there are endless questions on how that market plays out.
endpoints.news
January 16, 2026 at 5:04 PM
#JPM26 takeaway? GLP-1s are hot. “Every time you mention GLP-1, I’m going to charge you $5. I’m going to donate it to, I don’t know, an injured Canadian seals fund or something like that," Sandoz CEO Richard Saynor said.
endpoints.news/jpm26-sandoz...
endpoints.news/jpm26-sandoz...
ImmunityBio's off-the-shelf cell therapy shows early promise in rare form of lymphoma.
endpoints.news/immunitybio-...
endpoints.news/immunitybio-...
ImmunityBio's cell therapy posts encouraging early results in rare form of lymphoma
ImmunityBio's CAR-NK cell therapy with Rituxan shows complete responses in 2 of 4 Waldenström lymphoma patients, with responses lasting 7 and 15 months in ongoing Phase 1 trial.
endpoints.news
January 16, 2026 at 4:36 PM
ImmunityBio's off-the-shelf cell therapy shows early promise in rare form of lymphoma.
endpoints.news/immunitybio-...
endpoints.news/immunitybio-...
Reposted by Endpoints News
Scribe Therapeutics, a #CRISPR gene editing company cofounded by Jennifer Doudna in 2017, plans to start its first clinical trial this summer. The startup's lead program is an epigenetic editor targeting PCSK9 to lower cholesterol. More details in @endpts.com: endpoints.news/scribe-thera...
Scribe Therapeutics plans to test cholesterol-lowering epigenetic editing therapy
The company’s lead program is an epigenetic silencing therapy designed to turn off genes without altering the underlying genetic code.
endpoints.news
January 14, 2026 at 9:40 PM
Scribe Therapeutics, a #CRISPR gene editing company cofounded by Jennifer Doudna in 2017, plans to start its first clinical trial this summer. The startup's lead program is an epigenetic editor targeting PCSK9 to lower cholesterol. More details in @endpts.com: endpoints.news/scribe-thera...
Ocugen reported interim Phase 2 data showing its gene therapy reduced lesion size in geographic atrophy patients, though results came from a small subset of the trial.
Ocugen unwraps mid-stage data for eye disease gene therapy
Eye disease gene therapy developer Ocugen reported positive interim Phase 2 data for its geographic atrophy program from a small number of patients.
endpoints.news
January 15, 2026 at 8:41 PM
Ocugen reported interim Phase 2 data showing its gene therapy reduced lesion size in geographic atrophy patients, though results came from a small subset of the trial.
At #JPM26, Fosun Pharma laid out its ambition to become a global drugmaker, betting on in-house development and worldwide launches rather than just licensing assets to Big Pharma.
Inside Fosun Pharma's ambition to be a global drug company
Shanghai Fosun Pharmaceutical aims to build itself into a global drug innovator, co-president Xingli Wang told Endpoints News at the JP Morgan Healthcare Conference.
endpoints.news
January 15, 2026 at 6:57 PM
At #JPM26, Fosun Pharma laid out its ambition to become a global drugmaker, betting on in-house development and worldwide launches rather than just licensing assets to Big Pharma.
J&J reported a Phase 3 win for Tecvayli in earlier-line multiple myeloma, cutting the risk of progression or death by 71% and supporting a move into earlier treatment settings.
endpoints.news/jj-reports-p...
endpoints.news/jj-reports-p...
J&J reports positive Phase 3 data for Tecvayli in earlier blood cancer setting
J&J's Tecvayli shows 71% reduced risk of disease progression/death vs standard care in Phase 3 multiple myeloma trial, supporting potential earlier-line expansion
endpoints.news
January 15, 2026 at 3:21 PM
J&J reported a Phase 3 win for Tecvayli in earlier-line multiple myeloma, cutting the risk of progression or death by 71% and supporting a move into earlier treatment settings.
endpoints.news/jj-reports-p...
endpoints.news/jj-reports-p...
The Novo Nordisk Foundation is committing more than $850M over the next decade to the BioInnovation Institute, backing more life science and deep tech startups across Europe.
endpoints.news/novo-nordisk...
endpoints.news/novo-nordisk...
Novo Nordisk Foundation to inject $850M+ into life science incubator over the next decade
The Novo Nordisk Foundation is committing $857 million, allowing the BioInnovation Institute to support more startups per year.
endpoints.news
January 15, 2026 at 2:29 PM
The Novo Nordisk Foundation is committing more than $850M over the next decade to the BioInnovation Institute, backing more life science and deep tech startups across Europe.
endpoints.news/novo-nordisk...
endpoints.news/novo-nordisk...
How’s biopharma feeling heading into 2026? We asked everyone at Endpoints at #JPM26 — and the answers land somewhere between breakthrough and cautious optimism.
Follow the latest from San Francisco in our live blog: endpoints.news/jpm26-day-3-...
Follow the latest from San Francisco in our live blog: endpoints.news/jpm26-day-3-...
January 14, 2026 at 9:42 PM
How’s biopharma feeling heading into 2026? We asked everyone at Endpoints at #JPM26 — and the answers land somewhere between breakthrough and cautious optimism.
Follow the latest from San Francisco in our live blog: endpoints.news/jpm26-day-3-...
Follow the latest from San Francisco in our live blog: endpoints.news/jpm26-day-3-...
At #JPM26, pharma leaders said the US should focus on fixing its own biopharma system, not slowing China’s rise in drug development.
Drugmakers and investors want US reforms, not to slow down China
Pfizer CEO Albert Bourla and others at JP Morgan Healthcare Conference advocate for US reforms to compete with China, rather than protectionist measures, amid increased US-China pharma deals.
endpoints.news
January 14, 2026 at 6:40 PM
At #JPM26, pharma leaders said the US should focus on fixing its own biopharma system, not slowing China’s rise in drug development.
#JPM26 day 3: As the conference winds down, we’re tracking updates from WuXi AppTec and AbbVie — plus reactions from Lilly’s CEO, who says he’s unfazed by rising competition. Follow along for the latest from San Francisco.
#JPM26 live blog day 3: Lilly CEO is unfazed by competitors
JP Morgan Healthcare Conference: Lilly & Novo debate obesity pill requirements, Pfizer CEO warns of China competition, and Flagship's Afeyan disagrees with Nelsen on biotech intensity.
endpoints.news
January 14, 2026 at 4:13 PM
#JPM26 day 3: As the conference winds down, we’re tracking updates from WuXi AppTec and AbbVie — plus reactions from Lilly’s CEO, who says he’s unfazed by rising competition. Follow along for the latest from San Francisco.
Q&A: Bristol Myers CEO Chris Boerner talks megamergers, the outlook under Trump in 2026, and why brain health is shaping up as pharma’s next frontier.
Q&A: Bristol Myers CEO Chris Boerner on megamergers, Trump in 2026, and brain health as the 'next frontier'
Bristol Myers Squibb CEO Chris Boerner sat down with Endpoints News for a wide-ranging discussion of the year ahead and his take on the future of Bristol and the pharma industry.
endpoints.news
January 14, 2026 at 3:08 PM
Q&A: Bristol Myers CEO Chris Boerner talks megamergers, the outlook under Trump in 2026, and why brain health is shaping up as pharma’s next frontier.
Exclusive: HHS has removed members of a key advisory panel overseeing the childhood vaccine injury compensation program, raising questions about the future of the board amid potential changes under RFK Jr.
Exclusive: HHS ousts members of key advisory board for childhood vaccine injury program
The future of an advisory panel that reports to the HHS secretary on vaccine injury compensation appears to be in limbo after some members were told they were being removed.
endpoints.news
January 13, 2026 at 10:09 PM
Exclusive: HHS has removed members of a key advisory panel overseeing the childhood vaccine injury compensation program, raising questions about the future of the board amid potential changes under RFK Jr.
Endpoints reporters wrapped up our Main Stage programming with a roundtable on the regulatory environment, China, and everything else they're watching for the year ahead.
Thanks so much for joining us at the Endpoints at #JPM26 event. Keep following along for more of our coverage out of JPM.
Thanks so much for joining us at the Endpoints at #JPM26 event. Keep following along for more of our coverage out of JPM.
January 13, 2026 at 9:11 PM
Endpoints reporters wrapped up our Main Stage programming with a roundtable on the regulatory environment, China, and everything else they're watching for the year ahead.
Thanks so much for joining us at the Endpoints at #JPM26 event. Keep following along for more of our coverage out of JPM.
Thanks so much for joining us at the Endpoints at #JPM26 event. Keep following along for more of our coverage out of JPM.
Who’s afraid of OpenAI? Not digital health companies, apparently. @shelbylivingston.bsky.social explores the potential competition posed by the AI giant in today’s Health Tech.
Who’s afraid of OpenAI?
Digital health companies like OpenEvidence, UpToDate, and Atropos Health face competition from OpenAI's ChatGPT for Healthcare, though they claim differentiation through specialization.
endpoints.news
January 13, 2026 at 8:06 PM
Who’s afraid of OpenAI? Not digital health companies, apparently. @shelbylivingston.bsky.social explores the potential competition posed by the AI giant in today’s Health Tech.
Live from Endpoints at #JPM26: Nobel Laureate Fred Ramsdell worries that the US is ceding its leadership position on cell therapy to China. "I think we risk losing that if we don't continue to invest in this field." Join us virtually for the rest of the day’s programming: events.endpoints.news/jpm26
January 13, 2026 at 7:00 PM
Live from Endpoints at #JPM26: Nobel Laureate Fred Ramsdell worries that the US is ceding its leadership position on cell therapy to China. "I think we risk losing that if we don't continue to invest in this field." Join us virtually for the rest of the day’s programming: events.endpoints.news/jpm26
AbbVie has struck a MFN deal to lower drug prices in Medicaid and will also participate in TrumpRx – Trump’s direct-to-patient platform expected to launch this year.
AbbVie reaches MFN deal with the White House, pledges billions to US manufacturing
AbbVie has struck a 'most favored nation' deal with the White House to lower drug prices, the second-to-last of the 17 pharma companies to reach an agreement after facing a demand from President Donal...
endpoints.news
January 13, 2026 at 6:29 PM
AbbVie has struck a MFN deal to lower drug prices in Medicaid and will also participate in TrumpRx – Trump’s direct-to-patient platform expected to launch this year.
Layoffs are coming for Sonoma's Seattle and South SF offices affecting "all levels and functions", a Sonoma spokesperson told Endpoints News.
endpoints.news/treg-biotech...
endpoints.news/treg-biotech...
Treg biotech Sonoma sheds staff after getting new CEO
Sonoma Biotherapeutics cuts workforce across offices under new CEO Stephen Dilly, aiming to extend R&D through 2027. Company's lead asset SBT-77-7101 continues clinical testing.
endpoints.news
January 13, 2026 at 4:35 PM
Layoffs are coming for Sonoma's Seattle and South SF offices affecting "all levels and functions", a Sonoma spokesperson told Endpoints News.
endpoints.news/treg-biotech...
endpoints.news/treg-biotech...
#JPM26 Day 2 – Yesterday we got an update from Amgen on its obesity shot MariTide and insights on the future of biopharma from Novo Nordisk's Mike Doustdar. We're reporting live: endpoints.news/jpm26-day-2-...
#JPM26 live blog day 2: Novo’s plans in the clinic, AI talent wars and Nobel winner Fred Ramsdell
Amgen's MariTide obesity shot shows success in Phase 2, while Novo plans clinical program expansion. JPM Healthcare Conference continues with presentations from Novo, Lilly, and AstraZeneca.
endpoints.news
January 13, 2026 at 3:49 PM
#JPM26 Day 2 – Yesterday we got an update from Amgen on its obesity shot MariTide and insights on the future of biopharma from Novo Nordisk's Mike Doustdar. We're reporting live: endpoints.news/jpm26-day-2-...
Novartis will pay $50M upfront to license a peptide-based radiopharma asset from Chinese-based Zonsen PepLib Biotech.
endpoints.news/novartis-lic...
endpoints.news/novartis-lic...
Novartis licenses mysterious radiopharma asset from Chinese biotech
Novartis pays $50M upfront to license peptide-based radiopharmaceutical from Zonsen PepLib Biotech, expanding its radioligand therapy portfolio that includes Pluvicto and Lutathera.
endpoints.news
January 13, 2026 at 3:24 PM
Novartis will pay $50M upfront to license a peptide-based radiopharma asset from Chinese-based Zonsen PepLib Biotech.
endpoints.news/novartis-lic...
endpoints.news/novartis-lic...
Reposted by Endpoints News
Former Tome Bio leader John Finn is continuing his search for the ideal gene insertion tool at Basecamp Research. Today, the startup revealed its first AI-generated enzymes (large serine recombinases) that can insert genes without CRISPR. More in @endpts.com: endpoints.news/nvidia-partn...
Nvidia-partnered startup reveals AI-generated enzymes for precise gene insertion
Scientists at Basecamp Research say they have used “evolutionary AI models,” developed with help from chipmaker NVIDIA, to create a powerful new gene editing tool that can insert a new healthy gene in...
endpoints.news
January 12, 2026 at 9:40 PM
Former Tome Bio leader John Finn is continuing his search for the ideal gene insertion tool at Basecamp Research. Today, the startup revealed its first AI-generated enzymes (large serine recombinases) that can insert genes without CRISPR. More in @endpts.com: endpoints.news/nvidia-partn...
A startup partnered with Nvidia says it used AI to generate custom enzymes that can precisely insert genes into human DNA — a potential breakthrough for diseases like Duchenne and hemophilia. endpoints.news/nvidia-partn...
Nvidia-partnered startup reveals AI-generated enzymes for precise gene insertion
Scientists at Basecamp Research say they have used “evolutionary AI models,” developed with help from chipmaker NVIDIA, to create a powerful new gene editing tool that can insert a new healthy gene in...
endpoints.news
January 12, 2026 at 10:40 PM
A startup partnered with Nvidia says it used AI to generate custom enzymes that can precisely insert genes into human DNA — a potential breakthrough for diseases like Duchenne and hemophilia. endpoints.news/nvidia-partn...
Eli Lilly and Nvidia have announced a new 5-year deal which could be worth as much as $1B in an "AI co-innovation lab".
Lilly and Nvidia sign five-year deal worth as much $1B, will open Bay Area AI lab
Eli Lilly and Nvidia announce $1B partnership to open AI co-innovation lab in Bay Area, bringing scientists together for drug discovery and development initiatives
endpoints.news
January 12, 2026 at 9:08 PM
Eli Lilly and Nvidia have announced a new 5-year deal which could be worth as much as $1B in an "AI co-innovation lab".
AbbVie has jumpstarted #JPM26 with a $650M deal with China's RemeGen in PD-1xVEGF bispecifics race.
AbbVie jumps into PD-1xVEGF bispecifics race, paying $650M upfront to China's RemeGen
AbbVie is kicking off the JP Morgan Healthcare Conference with a deal in one of oncology’s hottest fields.
endpoints.news
January 12, 2026 at 6:55 PM
AbbVie has jumpstarted #JPM26 with a $650M deal with China's RemeGen in PD-1xVEGF bispecifics race.
Biopharma's kick-off to the year is finally upon us: Today is day 1 of #JPM26 and our team will be updating you live throughout the day with any developments
endpoints.news/jpm26-day-1-...
endpoints.news/jpm26-day-1-...
#JPM26 live blog day 1: IPOs, China and cautious optimism
Manas AI, founded by Siddhartha Mukherjee and Reid Hoffman, partners with Schrödinger for three drug programs. JPM Healthcare Conference begins with Novo Nordisk CEO speaking.
endpoints.news
January 12, 2026 at 3:47 PM
Biopharma's kick-off to the year is finally upon us: Today is day 1 of #JPM26 and our team will be updating you live throughout the day with any developments
endpoints.news/jpm26-day-1-...
endpoints.news/jpm26-day-1-...
Moderna's deals team is busy with "a number of opportunities," the CEO told us ahead of their presentation at #JPM26
endpoints.news/moderna-ceo-...
endpoints.news/moderna-ceo-...
Moderna CEO says deals team is reviewing 'a number of opportunities'
Moderna CEO Bancel discusses deals, cancer therapy launch plans, and vaccine challenges amid scrutiny. Company enters 2026 with $8.1B cash as it awaits FDA guidance on combo Covid-flu vaccine.
endpoints.news
January 12, 2026 at 2:36 PM
Moderna's deals team is busy with "a number of opportunities," the CEO told us ahead of their presentation at #JPM26
endpoints.news/moderna-ceo-...
endpoints.news/moderna-ceo-...